PTEN and breast carcinoma: Additionally, AKT1-3 mutations and/or amplifications, PDK1 amplification, PTEN and TSC1/2 inactivating mutation, and deletion or epigenetic silencing, which cause hyperactivation of the pathway, have also been found in breast cancer and have been suggested to hold prognostic or predictive value [10,12,13,14].